New hope for AML patients who fail venetoclax?
NCT ID NCT07471841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Participants take olutasidenib pills twice daily; after three cycles, azacitidine may be added if remission is not achieved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olutasidenib (with optional azacitidine)
What this could lead to
If successful, this could offer a new treatment option for AML patients whose cancer has stopped responding to venetoclax.
What could go wrong
This is a small, early-phase pilot study with only 25 participants, so results may not apply broadly. Adding azacitidine is optional and not standardized, which could affect outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Wake Forest Baptist Medical Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact